A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 308 participants.

Also called NCT07803679

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 308 participants (planned count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07803679
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07803679. Randomized; single masking; primary purpose treatment. Start 2027-01-31 (anticipated); primary completion 2029-04-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
Condition
Hypercholesterolemia
Condition
Atheroma
Intervention (Drug)
Evolocumab
Intervention (Drug)
Routine Lipid Management
Intervention (Device)
Autoinjector
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct07803679
Content hash
b1d86758a83065fcd81ba9c6ceede28d9aa80d488c2769227bfee78b543ba9ad